spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Rentschler Biotechnologie GmbH Announces Transition into a European Corporation Called Rentschler Biopharma SE

Rentschler Biotechnologie GmbH

Rentschler Biotechnologie GmbH announced that the Company has successfully transitioned into a European corporation (SE) with entry into the German commercial register on October 1, 2017

Laupheim, Germany, October 4, 2017 – Rentschler Biotechnologie GmbH, a leading contract development and manufacturing organization (CDMO) for biopharmaceuticals, today announced that the Company has successfully transitioned into a European corporation (SE) with entry into the German commercial register on October 1, 2017. The Company is operating as Rentschler Biopharma SE with immediate effect. There will be no operational changes for clients or employees of the family-owned company due to the transition.

“With our transition to Rentschler Biopharma SE, we emphasize our long-term international corporate identity, while the core business remains unaffected. In future, this legal form of company strengthens our position as a full-service CDMO and ensures our place as a leader in this industry,” commented Prof. Dr. Nikolaus F. Rentschler, Owner of Rentschler Biopharma SE. “Our proven service offering along the entire value chain – from bioprocess development through biomanufacturing to fill and finish of biopharmaceuticals – remains unchanged. This also applies to our company sites and manufacturing facilities as well as the existing client relations and importantly their contact persons.”

Over the recent years, Rentschler Biopharma has grown considerably and invested constantly in facilities so that capacities have more than doubled. With the expansion of our facilities, a continually growing number of employees has also been added to the Company. About 200 employees have been recruited in all business segments during the past year and a half. In the current fiscal year, over 120 additional positions are to be filled.

Rentschler will present itself as Rentschler Biopharma SE for the first time at the 23rd Annual International Partnering Conference BIO-Europe at booth 42/43. The conference takes place November 6-8, 2017 at Messe Berlin.

The term “European Corporation”, from the Latin: Societas Europaea (SE), is a legal form for incorporated companies in the European Union and the European Economic Area and enables the foundation of companies according to standardized legal principles.

About Rentschler Biopharma SE
Rentschler Biopharma SE, located in Laupheim, Germany, is a leading contract development and manufacturing organization (CDMO) for bioprocess development and manufacturing of biopharmaceuticals as well as for related consulting activities in terms of project management and regulatory support. The Company's clients include innovative biotech companies and major pharmaceutical companies around the world. Many years of experience and excellence in finding solutions as well as certified quality management and advanced technologies ensure Rentschler Biopharma's high quality standards. Rentschler Biopharma is a family-owned company employing approximately 750 people. For further information, please visit www.rentschler-biopharma.com.

Contact
Rentschler Biopharma SE
Dr. Marion Schrader
Senior Director Company Communication and Public Relations marion.schrader@rentschler-biopharma.com
phone +49 7392 701-0
email info@rentschler.de
web www.rentschler.de
email Erwin-Rentschler-Str. 21, 88471 Laupheim
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Recipharm and Laccure agree commercial collaboration


More info >>


White Papers

Clinical Trial Site Contracting: The Conservative, Progressive and Hybrid Models

DrugDev

For the last 20 years, pharmaceutical companies have turned to a variety of clinical outsourcing solutions to reduce costs and improve timelines, enabling them to focus on their core value of research and development. In today’s tightly competitive market, companies are constantly striving for ways to further cut costs and reduce study startup cycle times, while maintaining quality. One of the key cost factors in global R&D spending, estimated at around $102 billion per Kalorama market research, is the cost of conducting clinical trials. CRO’s, which account for about 30% of the total R&D spending, have risen to the challenge of the clinical, technical and administrative management of these trials. But some pharmaceutical companies question how much control to relinquish to vendor partners, especially in the legal arena, due to potential ramifications.
More info >>

Industry Events

Temperature Controlled Logistics 2018

29 January - 1 February 2018, Twickenham Stadium, London

Each January for the past 16 years, more than 400 senior supply chain, logistics, storage, regulation and quality experts from the pharmaceutical industry have gathered at the TCL Forum for the largest, longest running and most comprehensive cold chain and ambient logistics conference in Europe.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement